ID: MRFR/Pharma/1674-HCR | 85 Pages | Published By Rahul Gotadki on March 2023
The Benzodiazepine Market is depicted to witness a substantial CAGR of 2.30%. In the year 2030, the market value was spiked up to signifiacant value Therefore, the market will further increase substantially in the studied forecast period 2022-2030. The Benzodiazepine belongs to the psychoactive class of drugs. It is basically used for treating various mental diseases such as panic disorder, anxiety, alcohol withdrawal, seizures, and others.
They also have sedation properties which are also helpful in general anaesthesia, seizures, agitation, muscle spasms, etc. In the years 2005-2008, around 11% of Americans above 12 years of age took medicines for anxiety treatment. Also, the improvement of Xanax and healthcare programs improved the Benzodiazepine Market Growth. According to the Benzodiazepine Industry Analysis by the International Control Board, India (19%), Germany (10%), Italy (32%), and China (11%) were among the notable manufacturers of benzodiazepine.
The COVID-19 disease started to spread across the world in late 2019 and the initial months of 2020. It led to the financial disruption of various countries across the world. It created a huge gap between medical care and the demand for psychological management. Also, the use of required medication for COVOD-1 treatment caused negative drug interaction. Therefore, the Benzodiazepine Market was significantly disturbed with the advent of COVID-19 disease
The increasing cases of mental disorders across various countries across the world are anticipated to drive the Benzodiazepine Market. Also, the growing population of the older generation suffering from various mental disorders such as insomnia, Alzheimer's, etc. will further enhance the Industry Growth in the upcoming years.
The side effects of the benzodiazepine medicines are considered to be a major restraint for the market. Along with that, the higher chances of drug misuse and dependence on these medicines can further lead to death. Therefore, these restraints can be a significant threat to the Benzodiazepine Market Growth.
The adoption of a sedentary lifestyle can lead to various mental disorders such as agitation, anxiety, and many more. Therefore, with these types of rising cases, the Benzodiazepine Market will grow at a notable rate.
The availability of other alternatives of benzodiazepine drugs can be challenging for the market to compete. Also, a poor supply chain and lack of skilled workers can slow down the production of these medicines.
The Compound Annual Growth Rate (CAGR) of the Benzodiazepine Market is depicted to reach up to 2.4%. Previously in 2020, the market recorded immense revenue of USD 2055 Million. Therefore, the market revenue will increase significantly in the studied forecast period 2021-2028. The drivers such as the growing need for psychoactive medicines will play an important role in enhancing the market growth in the forthcoming years.
Value Chain Analysis
The increasing cases of mental disorders in the past several years are anticipated to emerge as a great advantage. It has further improved the Benzodiazepine Market Trends that will improve the market growth simultaneously. Also, the developments, acquisitions, mergers, etc. by key players will be further evaluated to propel the Benzodiazepine Market Growth.
The Benzodiazepine Market segments are divided into product, application, and time of action. Based on application, the Market is segmented into Insomnia, Anxiety Disorders, Alcohol Withdrawal, Seizures, Agitation, Muscle Spasms, Anaesthesia Supplements, and Others.
Based on Product Type, the Benzodiazepine Market is bifurcated into Diazepam, Alprazolam, Clonazepam, and Lorazepam.
Based on Action Time, the Benzodiazepine Market is divided into Ultra-Short Acting, Long Acting, and Short-Acting.
Based on geography, the Benzodiazepine Market Size is segmented into the Americas, Asia-pacific, Africa and the Middle East, and Europe. The Americas is divided into North America and Latin America. North America is anticipated to hold the largest share in the market. The significant technological development, better healthcare infrastructure are some crucial reasons for the largest share.
Secondly, Europe is depicted to hold the second-largest Benzodiazepine Market Share in the forecast period. The growing investments for development and research are the drivers of this region.
On the other hand, the Asia-Pacific region is evaluated to witness the fastest market growth in the studied forecast period. China, India, South Korea are playing a crucial role in boosting market growth in the future years.
Lastly, Africa and the Middle East region will also have notable growth in the upcoming years. The gradual development and growing awareness in this region can improve the market growth.
The Benzodiazepine Market is fragmented with the presence of various key players. These key players apply various market strategies such as partnerships, new product launches, market analysis, mergers, and many more. These strategies help the key players to enhance their business portfolio and geographical withhold. Some of the key players in the Benzodiazepine Market are listed below.
The report overview of the Benzodiazepine Market Analysis is listed below.
Report Score and Segmentation
The report score is to highlight important information about Benzodiazepine Market in the studied forecast period 2021-2028. It covers information such as market challenges, opportunities, CAGR market value, recent development, and many more. The information provided in this report is collected from various primary and secondary sources.
|Market Size||Significant Vlue|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Applications, Time of action|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer, Inc., Sanofi S.A. and Merck & Co., Inc.|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Benzodiazepine market is projected grow at approximately 2.30% CAGR during the assessment period (2022-2030).
Growing prevalence of anxiety and insomnia and government funding support for R&D are the major tailwinds pushing the growth of the global Benzodiazepine market
North America holds the largest share in the global Benzodiazepine market, followed by Europe and the Asia Pacific, respectively.
Eli Lilly and Company, AstraZeneca plc, Forest Laboratories, Inc., H. GlaxoSmithKline plc, Lundbeck A/S, Merck & Co., Inc., Johnson & Johnson, Sanofi S.A., and Pfizer, Inc., are some of the major players operating in the Benzodiazepine market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global Benzodiazepine market adopt to gain a larger competitive advantage.